全文获取类型
收费全文 | 6847篇 |
免费 | 409篇 |
国内免费 | 27篇 |
专业分类
耳鼻咽喉 | 59篇 |
儿科学 | 169篇 |
妇产科学 | 95篇 |
基础医学 | 1033篇 |
口腔科学 | 102篇 |
临床医学 | 558篇 |
内科学 | 1601篇 |
皮肤病学 | 94篇 |
神经病学 | 668篇 |
特种医学 | 266篇 |
外国民族医学 | 1篇 |
外科学 | 1128篇 |
综合类 | 42篇 |
一般理论 | 3篇 |
预防医学 | 433篇 |
眼科学 | 40篇 |
药学 | 464篇 |
中国医学 | 4篇 |
肿瘤学 | 523篇 |
出版年
2023年 | 22篇 |
2022年 | 56篇 |
2021年 | 140篇 |
2020年 | 70篇 |
2019年 | 95篇 |
2018年 | 148篇 |
2017年 | 103篇 |
2016年 | 107篇 |
2015年 | 142篇 |
2014年 | 190篇 |
2013年 | 314篇 |
2012年 | 395篇 |
2011年 | 417篇 |
2010年 | 293篇 |
2009年 | 242篇 |
2008年 | 392篇 |
2007年 | 444篇 |
2006年 | 356篇 |
2005年 | 428篇 |
2004年 | 403篇 |
2003年 | 389篇 |
2002年 | 337篇 |
2001年 | 132篇 |
2000年 | 130篇 |
1999年 | 128篇 |
1998年 | 81篇 |
1997年 | 84篇 |
1996年 | 65篇 |
1995年 | 57篇 |
1994年 | 52篇 |
1993年 | 47篇 |
1992年 | 77篇 |
1991年 | 50篇 |
1990年 | 68篇 |
1989年 | 61篇 |
1988年 | 52篇 |
1987年 | 45篇 |
1986年 | 34篇 |
1985年 | 30篇 |
1984年 | 34篇 |
1983年 | 30篇 |
1982年 | 26篇 |
1981年 | 20篇 |
1980年 | 27篇 |
1979年 | 22篇 |
1978年 | 28篇 |
1974年 | 19篇 |
1973年 | 25篇 |
1932年 | 19篇 |
1931年 | 17篇 |
排序方式: 共有7283条查询结果,搜索用时 234 毫秒
101.
Although the lifetable methodology is a standard tool in epidemiology and risk assessment, there are a number of differences in the way it has been applied by various advisory committees that have attempted to estimate radiation risks. The most fundamental of these differences concerns the choice of parameter to be estimated: the "excess lifetime risk" is the difference in lifetime risks between exposed and unexposed populations; the "risk of exposure-induced death" is the lifetime risk of dying of a disease attributable to exposure. These two quantities are not the same, even at low doses. Although both quantities have some utility in risk assessment, the "risk of exposure-induced death" comes closer to capturing the total impact of exposure. Other differences between reported risk estimates include details of the calculations, the baseline rates and age distributions of the exposed population, the forms of the models for excess rates, handling of organ-specific doses, and the groupings of cancer sites. These issues are discussed theoretically and illustrated with comparisons of the BEIR V and UNSCEAR reports. Although the risk estimates from these two reports are similar for most cancer sites, it is shown that this happens to be the result of an approximate cancellation of a number of differences that could be quite large. 相似文献
102.
Voiding parameter values measured with ambulatory urodynamic monitoring (AM) are generally found to be different from those
measured with conventional cystometry (CMG). The reason for this is unclear, but might be related to differences in the voided
volume. To verify this hypothesis, we compared voidings from female patients at an initial bladder volume that was close to
the modal volume (that is, the volume most often voided by the patient as derived from frequency/volume charts) with voidings
at maximum cystometric capacity during a routine video urodynamic examination. A first group of 35 patients voided at the
modal volume before they did at capacity. The order was reversed in a second group of 12 patients. The dependence of the voiding
parameters on the voided volume and the order of the measurements were examined. It was found that the maximum flow rate depended
significantly on the voided volume, but the associated detrusor pressure did not. Urethral resistance and bladder contraction
strength were not volume dependent either. It was concluded that the differences between AM and CMG cannot be explained from
possible differences in the voided volume.
Received: 23 August 1999 / Accepted: 16 December 1999 相似文献
103.
Vinzenz Czerny, chairman and professor of surgery in Freiburg im Breisgau and in Heidelberg, Germany, is the typical example
of a prominent surgeon with an elegant technique, who was also a keen observer and scientist at the turn of the nineteenth
into the early twentieth century. Starting his career in Vienna, Austria, he can be looked upon as the most important disciple
of Theodor Billroth. Whereas Billroth may be regarded as the father of modern gastrointestinal surgery, Czerny can be considered
the father of modern surgery for intestinal malignancies and multimodal treatment. The early history of visceral cancer therapy
is linked with his career. He became a surgeon of the highest rank, with great clinical skill, rare judgment, and vision who
contributed essentially to the development of modern surgery. From his early education he maintained a lifelong affection
for the natural sciences and was an excellent physiologist and pathologist. During his professional life he successfully built
up a well deserved reputation for general and cancer surgery and for the introduction of radio- and chemotherapy into the
treatment of tumors. Czerny founded and chaired the first experimental Institute for Cancer Research in Germany. Two years
later, in 1908, he presided at the 2nd Congress of the International Society of Surgery/Société Internationale de Chirurgie
(ISS/SIC) in Brussels, a congress that was almost entirely devoted to the etiology of visceral cancer and the progress and
achievements of its treatment. Czerny left a clear legacy of opinion and methods on which the modern era of surgical cancer
treatment is based. 相似文献
104.
Superior vena cava syndrome is most often caused by lung carcinoma. Two cases are described in whom venous obstruction in the superior mediastinum was caused by local vascular fibrosis due to radiotherapy five and seven years earlier. The development of radiation injury to greater vessels is discussed, together with the possibilities for treatment of superior vena cava syndrome. 相似文献
105.
Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. 总被引:20,自引:0,他引:20
Hinrich A Wieder Bj?rn L D M Brücher Frank Zimmermann Karen Becker Florian Lordick Ambros Beer Markus Schwaiger Ulrich Fink J?rg Rüdiger Siewert Hubert J Stein Wolfgang A Weber 《Journal of clinical oncology》2004,22(5):900-908
PURPOSE: To evaluate the time course of therapy-induced changes in tumor glucose use during chemoradiotherapy of esophageal squamous cell carcinoma (ESCC) and to correlate the reduction of metabolic activity with histopathologic tumor response and patient survival. PATIENTS AND METHODS: Thirty-eight patients with histologically proven intrathoracic ESCC (cT3, cN0/+, cM0) scheduled to undergo a 4-week course of preoperative simultaneous chemoradiotherapy followed by esophagectomy were included. Patients underwent positron emission tomography with the glucose analog fluorodeoxyglucose (FDG-PET) before therapy (n = 38), after 2 weeks of initiation of therapy (n = 27), and preoperatively (3 to 4 weeks after chemoradiotherapy; n = 38). Tumor metabolic activity was quantitatively assessed by standardized uptake values (SUVs). Results Mean tumor FDG uptake before therapy was 9.3 +/- 2.8 SUV and decreased to 5.7 +/- 1.9 SUV 14 days after initiation of chemoradiotherapy (-38% +/- 18%; P <.0001). The preoperative scan showed an additional decrease of metabolic activity to 3.3 +/- 1.1 SUV (P <.0001). In histopathologic responders (< 10% viable cells in the resected specimen), the decrease in SUV from baseline to day 14 was 44% +/- 15%, whereas it was only 21% +/- 14% in nonresponders (P =.0055). Metabolic changes at this time point were also correlated with patient survival (P =.011). In the preoperative scan, tumor metabolic activity had decreased by 70% +/- 11% in histopathologic responders and 51% +/- 21% in histopathologic nonresponders. CONCLUSION: Changes in tumor metabolic activity after 14 days of preoperative chemoradiotherapy are significantly correlated with tumor response and patient survival. This suggests that FDG-PET might be used to identify nonresponders early during neoadjuvant chemoradiotherapy, allowing for early modifications of the treatment protocol. 相似文献
106.
Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients. 总被引:14,自引:0,他引:14
Alena Novakova-Jiresova Mieke M Van Gameren Rob P Coppes Harm H Kampinga Harry J M Groen 《Radiotherapy and oncology》2004,71(2):183-189
PURPOSE: To investigate the relevance of transforming growth factor-beta (TGF-beta) dynamics in plasma for identification of patients at low risk for developing pneumonitis as a complication of thoracic radiotherapy (RT). PATIENTS AND METHODS: Non-small cell lung cancer patients undergoing conventional RT were included in the prospective study. Concentrations of TGF-beta were measured in the patients' plasma prior to and weekly during 6 weeks of RT. The incidence of symptoms of early post-irradiation lung injury, i.e. symptomatic radiation pneumonitis, was correlated with TGF-beta parameters. RESULTS: Forty-six patients were included in the study. Eleven patients (24%) developed symptomatic radiation pneumonitis. Absolute TGF-beta plasma levels did not differ between the groups of patients without or with pneumonitis. However, patients who developed pneumonitis tended to show increases in TGF-beta levels in the middle of the RT course relative to their pre-treatment levels while TGF-beta plasma levels of patients who did not develop pneumonitis tended to decrease over the RT treatment. The difference in the relative TGF-beta dynamics between the groups reached marginal significance in the third week of the treatment (P = 0.055) but weakened towards the end of the RT course. The utility of TGF-beta testing was evaluated at each RT week based on the test's ability to yield more accurate estimate of complication probability in an individual patient compared to empirically expected probability in similar group of patients. The ratio of TGF-beta level at week 3/week 0 being <1 showed an ability to improve the prediction of freedom from pneumonitis, yet with a large degree of uncertainty (wide confidence intervals). The accuracy of prediction deteriorated at later time points (weeks 4, 5 and 6) rendering the end-RT ratios without predictive power. CONCLUSIONS: We observed a trend of plasma TGF-beta concentration to decrease below the pre-treatment value during the RT treatment in patients who did not develop pulmonary complications after the RT treatment. However, this trend was not consistent enough to warrant safe decision-making in clinical setting. 相似文献
107.
Konrad Streitberger Mireen Friedrich-Rust Hubert Bardenheuer Kristina Unnebrink Jürgen Windeler Hartmut Goldschmidt Gerlinde Egerer 《Clinical cancer research》2003,9(7):2538-2544
PURPOSE: The purpose is to investigate an additional antiemetic effect to ondansetron with needle acupuncture at P6 compared with nonskin-penetrating placebo acupuncture in patients undergoing high-dose chemotherapy and autologous peripheral blood stem cell transplantation. EXPERIMENTAL DESIGN: Eighty patients who were admitted to hospital for high-dose chemotherapy and autologous peripheral blood stem cell transplantation were included into a randomized placebo-controlled single-blind trial. The patients were randomized to receive acupuncture (n = 41) or noninvasive placebo acupuncture (n = 39) at the acupuncture point P6 30 min before first application of high-dose chemotherapy and the day after. All patients received 8 mg ondansetron/day i.v. as basic antiemetic prophylaxis. The main outcome measure was the rate of patients who either had at least one episode of vomiting or required any additional antiemetic drugs on the first 2 days of chemotherapy. RESULTS: The main outcome measure showed no significant difference (P = 0.82): 61% failure in the acupuncture group and 64% in the placebo acupuncture group (95% confidence interval of 3% difference: -18.1 and 24.3%). Comparing nausea, episodes of vomiting or retching and number of additionally required antiemetic drugs did not provide any discrepancy with the main result. CONCLUSIONS: This study suggests that in combination with ondansetron i.v., invasive needle acupuncture at P6 compared with nonskin-penetrating placebo acupuncture has no additional effect for the prevention of acute nausea and vomiting in high-dose chemotherapy. 相似文献
108.
Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. 总被引:1,自引:0,他引:1
Diana C J Spierings Elisabeth G E de Vries Wim Timens Harry J M Groen H Marike Boezen Steven de Jong 《Clinical cancer research》2003,9(9):3397-3405
PURPOSE: Several in vitro studies have shown that non-small cell lung cancer (NSCLC) cell lines are sensitive to apoptosis induction by the recombinant human (rh) tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death ligand, indicating that rhTRAIL might become an attractive molecule for treatment of NSCLCs. To investigate the therapeutic potential of rhTRAIL, the expression of TRAIL and its apoptosis-inducing receptors DR4 and DR5 was evaluated in tumors of stage III NSCLC patients. EXPERIMENTAL DESIGN: Before treatment, tumor biopsies from locally advanced NSCLC patients were obtained by bronchoscopy. DR4, DR5, and TRAIL expression were determined immunohistochemically in 87 tumors. Patients were randomized for treatment with 60 Gy radiotherapy with or without carboplatin as radiosensitizer. RESULTS: DR4, DR5, and TRAIL were expressed in 99%, 82%, and 91% of the tumors, respectively. Seventeen percent of the samples expressed only DR4 and no DR5. In NSCLCs with squamous cell differentiation, a typical staining pattern for DR4 and DR5 was observed. Cells from the basal layer were strongly positive, and the more mature cells were less positive or negative. An inverse staining pattern was observed for TRAIL. Poorly differentiated areas showed strong staining intensity for DR4, DR5, and TRAIL. DR5-positive staining was associated with increased risk of death (odds ratio, 5.76; 95% confidence interval, 1.04-31.93; P = 0.045). CONCLUSIONS: The majority of the locally irresectable stage III NSCLCs expressed at least one of the two death receptors for TRAIL. Therefore, these death receptors may provide a target for the use of rhTRAIL as a new adjunct in the treatment of stage III NSCLC. 相似文献
109.
Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tomography. 总被引:9,自引:0,他引:9
Christophe van de Wiele Christophe Lahorte Hubert Vermeersch D Loose Kris Mervillie Neil D Steinmetz Jean-Luc Vanderheyden Claude A Cuvelier Guido Slegers Rudi A Dierck 《Journal of clinical oncology》2003,21(18):3483-3487
PURPOSE: Radiolabeled annexin V may allow for repetitive and selective in vivo identification of apoptotic cell death without the need for invasive biopsy. This study reports on the relationship between quantitative technetium-99m- (99mTc-) 6-hydrazinonicotinic (HYNIC) radiolabeled annexin V tumor uptake, and the number of tumor apoptotic cells derived from histologic analysis. PATIENTS AND METHODS: Twenty patients (18 men, two women) suspected of primary (n = 19) or recurrent (n = 1) head and neck carcinoma were included. All patients underwent a spiral computed tomography (CT) scan, 99mTc-HYNIC annexin V tomography, and subsequent surgical resection of the suspected primary or recurrent tumor. Quantitative 99mTc-HYNIC annexin V uptake in tumor lesions divided by the tumor volume, derived from CT, was related to the number of apoptotic cells per tumor high-power field derived from terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end-labeling (TUNEL) assays performed on sectioned tumor slices. RESULTS: Diagnosis was primary head and neck tumor in 18 patients, lymph node involvement of a cancer of unknown primary origin in one patient, and the absence of recurrence in one patient. Mean percentage absolute tumor uptake of the injected dose per cubic centimeter tumor volume derived from tomographic images was 0.0003% (standard deviation [SD], 0.0004%) at 1 hour postinjection (PI) and 0.0001% (SD, 0.0000%) at 5 to 6 hours PI (P =.012). Quantitative 99mTc-HYNIC annexin V tumor uptake correlated well with the number of apoptotic cells if only tumor samples with no or minimal amounts of necrosis were considered. CONCLUSION: In the absence of necrosis, absolute 99mTc-HYNIC annexin V tumor uptake values correlate well with the number of apoptotic cells derived from TUNEL assays. 相似文献
110.
Sascha Fauser Hubert Kalbacher Nils Alteheld Kan Koizumi Tim U. Krohne Antonia M. Joussen 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2004,242(7):582-586
Background The anti-inflammatory drug etanercept may be an effective therapeutic agent in diabetic retinopathy. In order to further evaluate its potential, the pharmacokinetics and safety of this drug after intravitreal delivery were investigated.Methods After intravitreal administration of etanercept in rabbits, clinical examination, electroretinography (ERG), visually evoked potentials (VEP) and histology were evaluated. The pharmacokinetics and distribution of etanercept were analyzed using fluorescence-coupled protein at 0, 2, 4, and 8 weeks after injection in vitreous, retina, and choroid.Results No adverse effects and signs of toxicity were found. Etanercept showed peak concentrations after 4 weeks in the retina and choroid.Conclusions Intravitreally delivered etanercept is safe and results in high concentrations in the retina and choroid over a long period of time. 相似文献